Start main content

Anti-BQ antibody

Category :
Unit Price
Unit Size
1.2 mg/ml
Contact Us

Anti-BQ (BQ323636.1) antibody, clone D12   


Western blot

Western blot
(primary antibody: anti-BQ 1:500;
secondary antibody: anti-mouse 1:2,000)
Arrow indicates the target band.

Breast cancer is the most common female cancer. About 70% of breast cancer is estrogen receptor positive (ER+). Tamoxifen is an effective and common drug for adjuvant treatment. However, up to 50% of the ER+ breast cancer eventually develop resistance to tamoxifen. A robust biomarker that can reliably predict which cancers will develop tamoxifen resistance is of particular importance. BQ323636.1 is a splice variant of NCOR2 [1]. It contains 362 amino acids with a molecular mass 42.6 kDa. The detection of nuclear overexpression of BQ323636.1 by immunohistochemistry (IHC) in primary breast tumors was found to be strongly associated with the development of tamoxifen resistance (p=1.79 x 10-6; sensitivity: 52.9%, specificity: 72.0%) [2]. The antibody may be used in the clinical setting for predicting tamoxifen response of ER+ breast cancer patients.  





Anti-BQ (BQ323636.1) antibody, clone D12
Product name  Anti-BQ (BQ323636.1) antibody, clone D12 
Description Mouse monoclonal antibody against BQ323636.1 is an affinity purified mouse immunoglobulin, IgG1, which specifically recognizes the unique epitope of the BQ323636.1 protein. BQ323636.1 is a novel alternatively spliced isoform of human NCOR2. Monoclonal anti-BQ antibody is useful for detection of BQ323636.1 proteins by immunohistochemistry (IHC) on formalin-fixed paraffin embedded (FFPE) sections; immunofluorescence (IF); and western blot. 
Tested applications  IHC; IF; western blot 
Species reactivity  Human
Purification and storage 

Protein G purification (purity ≥ 90%).  

Store the antibody in 2°C to 8°C. Avoid freezing.   

Supplied at 1 mg/ml in phosphate buffered saline, pH7.4, with 0.05% sodium azide and 0.5% albumin. 

Recommended dilutions 

IHC 1:50 

IF 1:50 

Western blot 1:500 

For Research Use Only. Not for diagnostic or therapeutic use.



  1. Zhang LD, Gong C, Lau SLY, et al. SpliceArray Profiling of Breast Cancer Reveals a Novel Variant of NCOR2/SMRT That Is Associated with Tamoxifen Resistance and Control of ER alpha Transcriptional Activity. Cancer Research 2013;73(1):246-255
  2. Gong C, Man EPS, Tsoi H, et al. BQ323636.1, a Novel Splice Variant to NCOR2, as a Predictor for Tamoxifen-Resistant Breast Cancer. Clinical Cancer Research 2018;24(15):3681-3691


Work with us